Sodium-glucose cotransporter 2 inhibitors and the risk of urinary tract infections or genital infections in adult patients with type 2 diabetes mellitus: a systematic review and network Meta-analysis of randomized controlled trials
刘凤琪,柴三葆,赵厚宇,刘佐相,武珊珊,杨智荣,詹思延,孙凤
DOI: https://doi.org/10.3760/cma.j.cn115791-20211217-00668
2022-01-01
Abstract:Objective:To systematically evaluate the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on urinary tract infections or genital infections in patients with type 2 diabetes mellitus.Methods:We searched PubMed, EMbase, Web of Science, Clinical trials and Cochrane Library, as well as Chinese literature databases such as China national knowledge infrastructure (CNKI), Wanfang, VIP, and SinoMed databases from the establishment of the databases to 31st, August 2021 for randomized controlled trials (RCT) that involved SGLT2i and safety events of urinary tract infections or genital infections. A series of network Meta-analysis were performed on all available evidence. The titles, interventions, background medication, outcome events, sample size and other information of the included studies were extracted. In a multi-layered mesh Meta-analysis of all available evidence, the relative effect values of urinary tract infection or genital infection were showed as odds ratio (OR) values and 95% confidence intervals (95%CI).Results:A total of 100 studies were included, 97 of which reported urinary tract infections and 28 of which reported genital infections. The total sample size of SGLT2i group was 46 697, including Canagliflozin, Dapagliflozin, Bexagliflozin, Remogliflozin, Ertugliflozin and Henagliflozin, etc. The total sample size of the control group including other hypoglycemic drugs and placebo was 33 284. Other hypoglycemic drugs included dipeptidyl peptidase Ⅳ inhibitor (DPP-4i), insulin, sulfonylureas, etc. Some kinds of SGLT2i were associated with an increasing risk of urinary tract infections at different magnitude. The risk of urinary tract infection induced by Canagliflozin was lower than that of Dapagliflozin (OR=0.67, 95%CI 0.45-0.99), Bexagliflozin (OR=0.43, 95%CI 0.19-0.98) and Remogliflozin (OR=0.27, 95%CI 0.08-0.97). Ertugliflozin increased the risk of urinary tract infection (OR=1.21, 95%CI 1.04-1.40) compared with placebo. Compared with Henagliflozin and insulin, Bexagliflozin increased the risk of urinary tract infection with the OR values (95%CI) of 4.15 (1.08-15.95) and 12.16 (1.27-116.55), respectively. In addition, Hengglitazin reduced the risk of urinary tract infection (OR=0.15, 95%CI 0.03-0.80) compared with Remogliflozin. Compared with insulin and sulfonylureas, Remogliflozin might increase the risk of urinary tract infection with the OR values (95%CI) of 19.32 (1.65-226.07) and 5.82 (1.11-30.57), respectively. The results of network Meta-analysis also showed that SGLT2i significantly increased the risk of genital infections compared with other hypoglycemic drugs (OR=4.18,95%CI 2.33-7.53). A detailed comparison showed that SGLT2i had a higher risk of genital infection compared with DPP-4i (OR=3.26, 95%CI 1.18-9.06), in which Canagliflozin had an increased risk compared with DPP-4i (OR=3.80, 95%CI 1.08-13.39). Conclusions:In patients with T2DM, SGLT2i was associated with a higher risk of genital infections compared with other hypoglycemic drugs, especially DPP-4i. Dapagliflozin, Ertugliflozin, Bexagliflozin, and Remogliflozin were associated with increasing risk of urinary tract infections.